Foaming pharmaceutical composition and method for imparting pharmaceutical efficacy using the same

Abstract

To provide a foaming drug efficacy-imparting composition to be packed in a spray product, capable of exhibiting excellent diffusibility of an active ingredient even without increasing foam retention, the foaming drug efficacy-imparting composition capable of exerting excellent drug efficacy as well as having a superior use feeling.SOLUTION FOR THE PROBLEM: A foaming drug efficacy-imparting composition to be packed in a spray product includes: (A) an active ingredient, (B) surfactant, (C) organic solvent, and water. When the composition is sprayed for one second to a 300-mL measuring cylinder with a bottom area 11.3 cm2, a foam volume ratio of a maximum value X of a cubic volume of a foam immediately after spraying and a cubic volume Y of the foam one minute after the spraying is Y / X≤0.99.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a foaming medicament-imparting composition and a method for imparting a medicament using the same.

Background Art

[0002] Since foaming products can visually recognize the appearance of bubbles during use, many products with a favorable feeling in use exist. Therefore, various types of foaming products have been studied and developed conventionally.

[0003] For example, Patent Document 1 describes a foaming deodorant aerosol composition that can form bubbles that do not deflate for a long time and do not dry, leave the bubbles remaining on the surface of the malodor source without drying for a long time, cover the malodor source with the bubbles, and prevent the diffusion of malodor into the air. Further, Patent Document 2 describes a foaming aerosol composition in which the ejected stock solution becomes foamy, has good foam-forming properties even at normal temperature or low temperature, and is excellent in persistence, and thus is easy to use.

[0004] However, the aerosol compositions described in Patent Document 1 and Patent Document 2 are both designed to enhance the persistence of the bubbles after foaming. By enhancing the persistence of the bubbles, the exposure time to the object becomes longer, and it is said that the performance can be sufficiently exhibited. Further, it was considered that an aerosol composition with poor bubble persistence has a short exposure time to the object, and thus there is a risk that the performance cannot be sufficiently exhibited. Therefore, an aerosol composition that can exhibit excellent medicinal effects without enhancing the persistence of bubbles has been desired.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0006] The present invention has been made in view of the above problems, and in a foaming medicinal composition for filling an injection product, even if the persistence of bubbles is not enhanced, it exhibits excellent diffusibility of the active ingredient, can exhibit excellent medicinal effects, and provides a foaming medicinal composition excellent in usability. This is the problem.

Means for Solving the Problems

[0007] As a result of intensive studies to achieve the object of the present invention, the present inventors have found that in a foaming medicinal composition for filling an injection product, the foam volume ratio, which is the change rate of the volume of bubbles after injection, is within a specific range. It was found to be important for improving the diffusibility, medicinal effect, and usability of the active ingredient, and the present invention was completed.

[0008] The present invention has found that the following configuration exhibits excellent effects for achieving the above object. (1) In a foaming medicinal composition for filling an injection product, the composition contains (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water, when the composition is injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm 2 for 1 second, the foam volume ratio, which is the ratio of the maximum value X of the volume of bubbles immediately after injection to the volume Y of bubbles 1 minute after injection, is a foaming medicinal composition in which Y / X ≤ 0.99. (2) The (C) organic solvent is one or more selected from the group consisting of hydrocarbon solvents, alcohol solvents, and glycol solvents. The foaming medicinal composition according to (1). (3) The (C) organic solvent is formulated in an amount of 0.5 to 30% by mass. The foaming medicinal composition according to (1) or (2). (4) The weight ratio of the (A) active ingredient to the (C) organic solvent is 10 ≤ (C) / (A) ≤ 700. The foaming medicinal composition according to any one of (1) to (3). (5) The foaming pharmaceutical composition according to any one of (1) to (4) wherein Y / X ≦ 0.70. (6) The foaming pharmaceutical composition according to any one of (1) to (5) wherein the pH of the composition is 5.0 to 12.0. (7) The foaming pharmaceutical composition according to any one of (1) to (6) wherein the surfactant is a nonionic surfactant and / or an amphoteric surfactant. (8) The foaming pharmaceutical composition according to any one of (1) to (7) wherein the (A) active ingredient is an aromatic deodorant component and the pharmaceutical effect is an aromatic deodorant effect. (9) The foaming pharmaceutical composition according to any one of (1) to (7) wherein the (A) active ingredient is an antifouling component and the pharmaceutical effect is an antifouling effect. (10) The foaming pharmaceutical composition according to any one of (1) to (7) wherein the (A) active ingredient is an antifungal component and the pharmaceutical effect is an antifungal effect. (11) An aerosol product obtained by filling an aerosol container with the composition according to any one of (1) to (10) and a propellant. (12) A spray product obtained by filling a spray container with the composition according to any one of (1) to (10). (13) A foaming pharmaceutical composition containing an (A) active ingredient, a (B) surfactant, a (C) organic solvent, and water, wherein the foam volume ratio, which is the ratio of the maximum value X of the volume of the foam immediately after spraying to the volume Y of the foam 1 minute after spraying when the composition is sprayed into a 300 mL graduated cylinder with a bottom area of 11.3 cm 2 for 1 second, is Y / X ≦ 0.99, and a pharmaceutical effect imparting method of spraying the foaming pharmaceutical composition.

Advantages of the Invention

[0009] The foaming medicament-imparting composition of the present invention is excellent in the diffusibility of the active ingredient and can exhibit excellent medicinal effects without enhancing the persistence of the foam. It also has excellent usability. In particular, when the active ingredient is an aromatic deodorant component, an antifouling component, or an antibacterial component, it is excellent in diffusibility and can exhibit excellent aromatic deodorant effects and also has excellent usability. Therefore, it is suitable for use in places where bad odors are a problem, such as toilets, drainage ditches, and washing tubs, and its practicality is extremely high.

Mode for Carrying Out the Invention

[0010] Hereinafter, the foaming medicament-imparting composition of the present invention and the medicament-imparting method using the same will be described in detail. However, the present invention is not intended to be limited to the configurations described in the following embodiments and examples. In the present specification, "~" includes the boundary values.

[0011] The component (A) active ingredient used in the present invention is not particularly limited, and examples thereof include aromatic deodorant components, antibacterial components, insect repellent components, antifouling components, anti-slime components, antibacterial components, virus inactivating components, and the like. It is one or more of these components.

[0012] The fragrant deodorizing components are not particularly limited, but components that mask bad odors or components that change into a pleasant scent through harmonized effects, such as fragrances, essential oils, etc., are used. Examples of fragrances include limonene such as d-limonene, pinene such as α-pinene and β-pinene, cymene such as p-cymene, hydrocarbon fragrances such as indene and caryophyllene, menthol such as linalool, geraniol, citronellol, and l-menthol, terpineol such as ethyl linalool, borneol, anisyl alcohol, β-phenethyl alcohol, p-menthane-3,8-diol, α-terpineol, and γ-terpineol, alcohol fragrances such as 1-hexenol, cis-3-hexen-1-ol, tetrahydrogeraniol, santalinol, cinnamyl alcohol, and cedrol, cineol such as calaxolide, β-naphthyl methyl ether, 1,4-cineole, and 1,8-cineole, ether fragrances such as ambroxide and p-cresyl methyl ether, phenolic fragrances such as anethole, eugenol, isoeugenol, vanillin, and ethyl vanillin, aldehyde fragrances such as octanal, nonanal, undecyl aldehyde, undecanal, decyl aldehyde, n-butyl aldehyde, isobutyl aldehyde, hexyl aldehyde, citral, citronellal, benzaldehyde, cinnamic aldehyde, anisaldehyde, cumin aldehyde, adoxal, amyl cinnamic aldehyde, and cyclamen aldehyde, ketone fragrances such as muscone, carvone, menthone, camphor, camphor, acetophenone, butyrophenone, tonalide, α-ionone, β-ionone, α-methyl ionone, β-methyl ionone, α-isomethyl ionone, β-isomethyl ionone, γ-methyl ionone, γ-isomethyl ionone, damascone, α-damascone, β-damascone, acetyl cedrene, cashmeran, cis-jasmone, and dihydrojasmone, lactone fragrances such as γ-butyrolactone, γ-nonalactone, γ-decalactone, γ-undecalactone, coumarin, cineole, ambred red, and jasmolactone, and formates such as geranyl formate, octyl acetate, geranyl acetate, benzyl acetate, cinnamyl acetate, tetrahydrogeranyl acetate, menthyl acetate, linalyl acetate, butyl propionate, benzyl acetate,Ester-based fragrances such as methyl benzoate, allyl hexanoate, allyl heptanoate, allyl cyclohexanepropionate, allyl amyl glycolate, amyl valerianate, amyl salicylate, isoamyl acetate, butyl acetate, ethyl butyrate, acetyl eugenol, isoamyl salicylate, allyl caproate, ethyl caproate, ethyl propionate, ethyl acetoacetate, methyl salicylate, citronellyl acetate, citronellyl formate, cinnamyl acetate, stearyl acetate, stearyl propionate, cedryl acetate, terpinyl acetate, etc.; acetal-based fragrances such as amyl cinnamic aldehyde dimethyl acetal, citral dimethyl acetal, etc.; indole, geranyl nitrile, citronellyl nitrile, acetaldehyde phenyl ethyl propyl acetate, tesalon, allantiole, linalool oxide, etc. The above fragrances can be used alone or in the form of compounded fragrances mixed with two or more of them. These are known as synthetic fragrances or extracted fragrances, etc.

[0013] Examples of essential oils include peppermint oil, orange oil, lemon oil, lavender oil, peppermint oil, eucalyptus oil, citronella oil, lime oil, yuzu oil, jasmine oil, hinoki oil, green tea essential oil, neroli oil, geranium oil, petitgrain oil, lemongrass oil, cinnamon oil, lemon eucalyptus oil, thyme oil, perilla oil, petitgrain oil, pine oil, rose oil, rosemary oil, camphor oil, aromatic oil, clary sage oil, sandalwood oil, spearmint oil, star anise oil, lavandin oil, oakmoss oil, ocochia oil, patchouli oil, tonka bean tincture, turpentine oil, vanilla bean tincture, basil oil, nutmeg oil, clove oil, bois de rose oil, cananga oil, cardamom oil, cassia oil, cedarwood oil, mandarin oil, tangerine oil, anise oil, bay oil, coriander oil, elemi oil, fennel oil, galbanum oil, hiba oil, hinoki oil, vetiver oil, bergamot oil, ylang-ylang oil, grapefruit oil, abies oil, action oil, almond oil, angelica root oil, pageil oil, mint oil, perchy oil, bois de valrose oil, kaya buti oil, cananga oil, capsicum oil, caraway oil, celery oil, Examples include cognac oil, cumin oil, dill oil, estragon oil, garlic oil, ginger oil, hop oil, sage oil, turpentine oil, etc. The above essential oils can be used alone, or components obtained by mixing two or more of the above essential oils can also be used.

[0014] The antifungal components are not particularly limited. For example, phenolic antifungal components such as isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, о-cresol, m-cresol, and p-cresol; benzalkonium salts such as benzalkonium chloride, benzalkonium methosulfate, and benzalkonium organic acid salts; benzethonium salts such as benzethonium chloride, benzethonium methosulfate, and benzethonium organic acid salts; cetylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium methosulfate, and cetylpyridinium organic acid salts; didecyldimethylammonium salts such as didecyldimethylammonium chloride and didecyldimethylammonium methosulfate; dilauryl dimethylammonium salts such as dilauryl dimethylammonium chloride and dilauryl dimethylammonium methosulfate; distearyldimethylammonium salts such as distearyldimethylammonium chloride and distearyldimethylammonium methosulfate; and cationic surfactant-based antifungal components such as 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dichloride, and 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dimethosulfate; biguanide-based antifungal components; azole-based antifungal components such as tebuconazole and enilconazole; fruit seed extract-based antifungal components such as grapefruit seed extract, kaki seed extract, and grape seed extract; glycerin monofatty acid ester-based antifungal components such as monolaurin, monocaprin, and monocaprylin; chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine dihydrochloride, and chlorhexidine-based antifungal components such as chlorhexidine; octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,Silicon-based antifungal components such as dodecyl diisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyl dimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyl dimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyl dimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, octadecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, etc.; carboxylic acid-based antifungal components such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, polylysine, or salts thereof; and other antifungal components such as dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver-based antifungal components such as silver zeolite, zinc pyrithione, thiamine lauryl sulfate, white egg protein, hydroxyalkyl chitosan or salts thereof, and antifungal fragrances. The above antifungal components can be used alone, or components mixed with two or more of the above antifungal components can also be used.

[0015] The insect repellent components are not particularly limited. For example, pyrethroid-based insect repellent components such as phenothrin, etofenprox, silafluofen, permethrin, cypermethrin, transfluthrin, metofluthrin, profenoflor, empenthrin, cyphenothrin, allethrin, prallethrin, phthalthrin, imiprothrin, monofluoroethrin, meperfluthrin, heptafluthrin, tefluthrin, resmethrin, flumethrin, pyrethrin, acrinathrin, bifenthrin, deltamethrin, tetramethrin, etc.; neonicotinoid-based insect repellent components such as dinotefuran, imidacloprid, clothianidin, etc.; broflanilide, deet, ikaridin, ethyl butylacetylaminopropionate (IR3535), p-menthane-3,8-diol, methyl acetate, peppermint oil, etc. can be mentioned. The above insect repellent components can be used alone, or components mixed with two or more of the above insect repellent components can also be used.

[0016] The antifouling components are not particularly limited. For example, alkyl glycoside-based antifouling components such as octyl glucoside, decyl glucoside, lauryl glucoside, myristyl glucoside, cetyl glucoside, etc.; quaternary ammonium salt-based antifouling components such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, dimyristyldimethylammonium chloride, dimyristyldimethylammonium methyl sulfate, didecyldimethylammonium methosulfate, etc.; quaternary ammonium salt polymer-based antifouling components such as dimethyldiallylammonium chloride homopolymer and copolymers of quaternary ammonium salts such as dimethyldiallylammonium chloride and acrylic acid derivatives such as acrylamide, acrylic acid, acrylate, etc.; fluorine-based antifouling components such as α-perfluorononenyl oxy-ω-methyl polyethylene oxide, fluorinated alkyl hydrophilic group-containing oligomers, fluorinated alkyl ester addition polymers, partially fluorinated alcohol-substituted glycols, etc.; alkylene oxide adducts of acetylene glycol, polyether-modified polysiloxanes, ethylenediaminetetraacetic acid and its salts, nitrilotriacetic acid and its salts, gluconic acid and its salts, etc. The above antifouling components can be used alone, or components mixed with two or more of the above antifouling components can also be used.

[0017] The anti-slime components are not particularly limited. For example, allyl isothiocyanate, trichloroisocyanuric acid, etc. The above anti-slime components can be used alone, or components mixed with two or more of the above anti-slime components can also be used.

[0018] The antibacterial components are not particularly limited. For example, phenolic antibacterial components such as isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, о-cresol, m-cresol, and p-cresol; benzalkonium salts such as benzalkonium chloride, benzalkonium methosulfate, and benzalkonium organic acid salts; benzethonium salts such as benzethonium chloride, benzethonium methosulfate, and benzethonium organic acid salts; cetylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium methosulfate, and cetylpyridinium organic acid salts; didecyldimethylammonium salts such as didecyldimethylammonium chloride and didecyldimethylammonium methosulfate; dilauryl dimethylammonium salts such as dilauryl dimethylammonium chloride and dilauryl dimethylammonium methosulfate; distearyldimethylammonium salts such as distearyldimethylammonium chloride and distearyldimethylammonium methosulfate; and cationic surfactant-based antibacterial components such as 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dichloride, and 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dimethosulfate; biguanide-based antibacterial components; azole-based antibacterial components such as tebuconazole and enilconazole; fruit seed extract-based antibacterial components such as grapefruit seed extract, kaki seed extract, and grape seed extract; glycerin monofatty acid ester-based antibacterial components such as monolaurin, monocaprin, and monocaprylin; chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine dihydrochloride, and chlorhexidine-based antibacterial components such as chlorhexidine; octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,Silicon-based antibacterial components such as dodecyl diisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyl dimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyl dimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyl dimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyl diethyl(3-triethoxysilylpropyl)ammonium chloride, octadecyl di-n-propyl(3-triethoxysilylpropyl)ammonium chloride, carboxylic acid-based antibacterial components such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, polylysine or their salts, dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver-based antibacterial components such as silver zeolite, zinc pyrithione, thiamine lauryl sulfate, white egg protein, hydroxyalkyl chitosan or its salts, etc. The above antibacterial components can be used alone, or components mixed with two or more of the above antibacterial components can also be used.

[0019] The virus inactivating components are not particularly limited. For example, phenolic virus inactivating components such as isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, o-cresol, m-cresol, and p-cresol; benzalkonium salts such as benzalkonium chloride, benzalkonium methosulfate, and benzalkonium organic acid salts; benzethonium salts such as benzethonium chloride, benzethonium methosulfate, and benzethonium organic acid salts; cetylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium methosulfate, and cetylpyridinium organic acid salts; didecyldimethylammonium salts such as didecyldimethylammonium chloride and didecyldimethylammonium methosulfate; dilauryl dimethylammonium salts such as dilauryl dimethylammonium chloride and dilauryl dimethylammonium methosulfate; distearyldimethylammonium salts such as distearyldimethylammonium chloride and distearyldimethylammonium methosulfate; and cationic surfactant-based virus inactivating components such as 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dichloride, and 1,4-bis[3,3´-(1-decylpyridinium)methyloxy]butane dimethosulfate; biguanide-based virus inactivating components; azole-based virus inactivating components such as tebuconazole and enilconazole; fruit seed extract-based virus inactivating components such as grapefruit seed extract, kaki seed extract, and grape seed extract; glycerin monofatty acid ester-based virus inactivating components such as monolaurin, monocaprin, and monocaprylin; chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine dihydrochloride, and chlorhexidine-based virus inactivating components such as chlorhexidine; octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,Silicon-based virus inactivating components such as dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, carboxylic acid-based virus inactivating components such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, polylysine or salts thereof, dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, silver-based virus inactivating components such as silver zeolite, zinc pyrithione, thiamine lauryl sulfate, albumen, hydroxyalkyl chitosan or salts thereof, etc. can be mentioned. The above virus inactivating components can be used alone, and components obtained by mixing two or more of the above virus inactivating components can also be used.

[0020] (A) The compounding amount of the component is preferably 0.01 to 10% by mass, more preferably 0.02 to 5% by mass, and still more preferably 0.05 to 2% by mass in the foaming medicament-providing composition.

[0021] As the surfactant (B) used in the present invention, any of anionic surfactants, nonionic surfactants, and amphoteric surfactants may be used. Examples of anionic surfactants include alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, α-olefin sulfonates, alkyl phosphate esters, polyoxyethylene alkyl ether sulfates, polyoxyethylene alkyl phenyl ether sulfates, polyoxyethylene alkyl ether phosphates, etc. Examples of nonionic surfactants include polyoxyethylene alkyl ethers such as polyoxyethylene oleyl ether, polyoxyethylene tridecyl ether, polyoxyethylene cetyl ether, polyoxyethylene 2-ethylhexyl ether, polyoxyethylene polyoxypropylene cetyl ether, polyoxyethylene polyoxypropylene 2-ethylhexyl ether and other polyoxyethylene polyoxypropylene alkyl ethers, polyoxyethylene alkyl phenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, fatty acid alkanolamides, alkyl polyglucosides such as lauryl polyglucoside, myristyl polyglucoside, coconut oil fatty acid diethanolamide, polyoxyethylene hydrogenated castor oil, etc. Examples of amphoteric surfactants include alkylamine oxides, coconut oil alkyl dimethylamine oxides, aminoacetic acid betaines, amidopropyl betaines, alkylamidopropyl hydroxysulfides, 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaines, etc. Among these surfactants, from the viewpoint of foaming properties, it is preferable to contain a nonionic surfactant and / or an amphoteric surfactant, more preferably to contain a nonionic surfactant, even more preferably to contain polyoxyethylene alkyl ether and / or polyoxyethylene polyoxypropylene alkyl ether, and even more preferably to contain a polyoxyethylene alkyl ether and / or polyoxyethylene polyoxypropylene alkyl ether having a branched alkyl chain. These surfactants can be used in combination of one or more kinds.In addition, it is preferable that 0.1 to 10% by mass of (B) surfactant is blended in the foaming pharmaceutical composition of the present invention. In this specification, cationic surfactants that are antifungal components, antibacterial components, antifouling components, or virus inactivating components are not treated as (B) surfactants.

[0022] The (C) solvent used in the present invention is not particularly limited. For example, hydrocarbon solvents such as normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbons, petrolatum, squalane, α-olefin oligomers, and squalane; alcohol solvents such as ethanol, 1-propanol, 2-propanol (IPA), 1-butanol, 2-butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, and 2-phenylethanol; glycol solvents such as 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether. These solvents can be used in combination of one or more, and it is preferable that 0.5 to 30% by mass of (C) solvent is blended in the foaming pharmaceutical composition of the present invention.

[0023] Examples of the water used in the present invention include purified water such as ion-exchanged water and reverse osmosis membrane water, ordinary tap water, industrial water, and deep ocean water. The blending amount of water is not particularly limited as long as solubility is maintained, but it is preferable that 50 to 99% by mass of water is blended in the foaming pharmaceutical composition of the present invention.

[0024] Furthermore, in the foaming pharmaceutical composition of the present invention, as other components, if necessary, algicides, chelating agents such as sodium citrate, pH adjusters such as citric acid, rust preventives such as sodium benzoate, pigments such as blue pigment, green pigment, and red pigment, antifouling agents, etc. may be appropriately blended within a range that does not impair the effects of the present invention.

[0025] In the present invention, when the foaming medicinal effect-imparting composition is injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm 2 for 1 second, the foam volume ratio, which is the ratio of the maximum value X of the foam volume immediately after injection to the foam volume Y 1 minute after injection, is preferably Y / X ≦ 0.99, and more preferably Y / X ≦ 0.70. After injecting the foaming medicinal effect-imparting composition of the present invention, when the foam volume ratio, which is the change rate of the foam volume, is within the above range, the diffusibility of the active ingredient is improved, and excellent medicinal effects can be exhibited.

[0026] The blending mass ratio of the (A) active ingredient and the (C) organic solvent in the foaming medicinal effect-imparting composition of the present invention is preferably 10 ≦ (C) / (A) ≦ 700, and more preferably 50 ≦ (C) / (A) ≦ 500. When (C) / (A) is within the above range, the diffusibility of the active ingredient is improved, and excellent medicinal effects can be exhibited.

[0027] The pH of the foaming medicinal effect-imparting composition of the present invention is preferably 5.0 to 12.0. Thereby, it becomes weakly acidic to basic, and it can be used even for metals that are easily corroded by strong acids, resulting in a foaming medicinal effect-imparting composition with high versatility.

[0028] The medicinal effect of the foaming medicinal effect-imparting composition of the present invention varies depending on the (A) active ingredient. For example, when the (A) component is an aromatic deodorant component, it has an aromatic deodorant effect; when the (A) component is a mold-proof component, it has a mold-proof effect; when the (A) component is an insect-proof component, it has an insect-proof effect; when the (A) component is an antifouling component, it has an antifouling effect; when the (A) component is an anti-slime component, it has an anti-slime effect; when the (A) component is an antibacterial component, it has an antibacterial effect; when the (A) component is a virus inactivating component, it has a virus inactivating effect. Further, when two or more components are used as the (A) active ingredient, the medicinal effect corresponds to the types of the components. For example, when the (A) component is an aromatic deodorant component and an insect-proof component, it has an aromatic deodorant effect and an insect-proof effect.

[0029] In addition, the foaming medicament-imparting composition of the present invention is filled into a trigger-type or pump-type spray container and used as a spray product in a spray form that does not require a propellant, or an aerosol form that is filled into a pressure-resistant container and contains a propellant. For the latter, the aerosol stock solution is put into an aerosol container. The propellant is not particularly limited, and examples include liquefied petroleum gas (LPG) such as propane, normal butane, and isobutane, liquefied gases such as normal pentane, isopentane, dimethyl ether (DME), and hydrofluoroolefin such as HFO1234ze, and compressed gases such as nitrogen gas, carbon dioxide gas, nitrous oxide, and compressed air. By pressurizing and filling these, the aerosol of the present invention can be provided. The aerosol can be a metered spray aerosol by providing a metering spray valve. The mixing ratio (volume ratio) of the aerosol stock solution and the propellant is preferably 10 / 90 to 60 / 40, more preferably 15 / 85 to 50 / 50, and even more preferably 20 / 80 to 40 / 60. As for the type of aerosol, either an aqueous aerosol or an oil-based aerosol can be formulated. In addition, the number, dimensions, and shape of the spray nozzles in the spray form or aerosol form are not particularly limited. As for the spray button, any button of a type that forms foam may be used, but a spout type or a button having a mechanical breakup mechanism is preferred.

[0030] The treatment targets of the foaming medicament-imparting composition of the present invention are not particularly limited, and examples include toilet bowls, bathtubs, drain pipes, washing tubs, window glasses, air conditioner filters, filters, aluminum fins of air conditioners, ventilation fans, screen doors, automobiles, etc. From the viewpoint of being easy to treat by spraying, it is suitable for use in toilet bowls, bathtubs, drain pipes, washing tubs, etc.

[0031] Note that the present invention is not limited to the above-described embodiments, and various modifications are possible within the scope shown in the claims. Embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention. Hereinafter, the effects of the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

Example

[0032] [Preparation of Foaming Medicinal Composition] (A) As components, perfume A (a lavender-scented perfume containing 15% d-limonene, 15% linalyl acetate, and 10% linalool), d-limonene, lavender oil, (B) As components, polyoxyethylene 2-ethylhexyl ether (hereinafter referred to as POE 2-ethylhexyl ether. Newcol 1008, manufactured by Nippon Emulsion Co., Ltd.), alkyl polyglucoside (carbon number 10-16, Glucopon 600 CSUP, manufactured by BASF Co., Ltd.), coconut oil alkyldimethylamine oxide (Cadena DMC-W, manufactured by Lion Specialty Chemicals Co., Ltd.), (C) As components, ethanol (manufactured by Fujifilm Wako Pure Chemical Corporation), 2-phenoxyethanol (Dawanol EPh, manufactured by Ando Parachem Co., Ltd.), 1-phenoxy-2-propanol (Dawanol PPh, manufactured by Dow Chemical Japan Co., Ltd.) were blended at the blending ratios (mass %) shown in Tables 1 and 2, and ion-exchanged water was added to make 100 mass % to adjust a foaming medicinal composition. This foaming medicinal composition was put into an aerosol container together with LPG as a propellant to prepare the aerosol products shown in Tables 1 and 2 (Examples 1 to 13). As the spray button, a button with a resin pipe having an inner diameter of 0.6 mm and a length of 10 cm (product number D94WHCD"3"-A-NP-23-100N-W, manufactured by Mitani Valve Co., Ltd.) was used. Also, the temperature of each aerosol product was adjusted to 25°C in a water bath, and it was sprayed into a 300 mL graduated cylinder with a bottom area of 11.3 cm 2 for 1 second, and the maximum value X of the volume of the foam immediately after spraying and the volume Y of the foam 1 minute after spraying were read from their respective scales to obtain the maximum value X of the volume and the volume Y, and the foam volume ratio (X / Y) was measured.

[0033] Similarly, as the component (A), a lavender fragrance containing 15% d-limonene, 15% linalyl acetate, and 10% linalool, and as the component (B), POE 2-ethylhexyl ether (Newcol 1008, manufactured by Nippon Emulsion Co., Ltd.) were blended at the blending ratios (mass %) shown in Table 3, and ion-exchanged water was added to make the total 100 mass % to prepare a foaming medicinal composition [L]. This foaming medicinal composition [L] was put into an aerosol container together with a propellant [G] (the volume ratio was set to [L] / [G] = 70 / 30), and the aerosol products shown in Table 3 were prepared. As the spray button, a button with a resin pipe having an inner diameter of 0.6 mm and a length of 10 cm (product number D94WHCD"3"-A-NP-23-100N-W, manufactured by Mitani Valve Co., Ltd.) was used. Also, the temperature of each aerosol product was adjusted to 25°C in a water bath, and it was sprayed into a 300 mL measuring cylinder with a bottom area of 11.3 cm 2 for 1 second, and the maximum value X of the volume of the foam immediately after spraying and the volume Y of the foam 1 minute after spraying were read from the respective scales to obtain the maximum value X of the volume and the volume Y, and the foam volume ratio (X / Y) was measured.

[0034]

Table 1

[0035]

Table 2

[0036]

Table 3

[0037] [Effect Test 1 (test results are described in Table 4)] (1) Diffusibility test of aromatic deodorant components 1. Two stainless steel cylinders (20 cm in diameter and 85 cm in length) were connected. The mouth at one end of the cylinder was pre-covered with aluminum foil with a hole approximately 7 cm square in the center (hereinafter referred to as the evaluation side). The mouth on the opposite side was left as it was without aluminum foil (hereinafter referred to as the sample side). 2. The sample was injected into a glass petri dish (9.8 cm in diameter and 1.8 cm in height) with an open top for 1 second, placed into the dish from the sample side, and positioned 10 cm from the end on the sample side inside the cylinder. Immediately, the mouth of the cylinder on the sample side was covered with aluminum foil. 4. The evaluator continuously smelled the odor inside the cylinder from the mouth on the evaluation side and measured the time from when the glass petri dish was placed until the fragrance was felt. The average measurement time was calculated by averaging the times measured by 10 evaluators and evaluated according to the following criteria. <Diffusibility of Aroma and Odor-Eliminating Components> ◎: (Average measurement time) ≤ 12 seconds 〇: 12 seconds < (Average measurement time) ≤ 17 seconds ×: 17 seconds < (Average measurement time)

[0038] (2) Efficacy (Aroma and Odor-Eliminating Effect) Test 1. Two stainless steel cylinders (20 cm in diameter and 85 cm in length) were connected. One end of the cylinder was pre-covered with aluminum foil with an opening (hereinafter referred to as opening A) in the lower half (hereinafter referred to as the sample side), and the opposite side was covered with aluminum foil with an opening (7 cm × 7 cm, hereinafter referred to as opening B) in the center (hereinafter referred to as the evaluation side). Further, on the evaluation side, an aluminum foil of a size that could cover opening B was pasted as the lid of opening B, and by opening and closing this, the opening and closing of opening B was made possible. 2. 0.5 mL of 1% aqueous ammonia was placed on top of a glass stand (9.8 cm in diameter and 1.8 cm in height), placed into the cylinder from the sample side, and positioned 10 cm from the end on the sample side inside the cylinder. In this state, the switch of a fan (manufactured by Nidec Servo, VE55B5) was turned on, and air was blown for 10 seconds. After 3.10 seconds, stop the fan, gently open the aluminum foil lid at the opening B on the evaluation side, and let the evaluator smell the odor inside the cylinder from the opening B. Evaluate the ammonia odor on a 6-point scale (0: odorless, 1: barely perceptible odor, 2: weak odor that can be recognized as what kind of odor, 3: easily perceptible odor, 4: strong odor, 5: intense odor) (let the evaluation score be S). 4. Remove the malodorous glass stand from the sample side. Next, inject the sample into a glass petri dish (diameter 9.8 cm, height 1.8 cm) with an open top for 1 second, put it in from the sample side, and place it 10 cm from the end on the sample side inside the cylinder, and let it stand for 10 seconds. 5. Similar to step 3 above, gently open the aluminum foil lid at the opening B on the evaluation side, and let the evaluator smell the odor inside the cylinder from the opening B. Evaluate the ammonia odor on a 6-point scale (0: odorless, 1: barely perceptible odor, 2: weak odor that can be recognized as what kind of odor, 3: easily perceptible odor, 4: strong odor, 5: intense odor) (let the evaluation score be T). 6. Calculate the deodorization rate of the ammonia odor by (S - T) / S × 100. Average the results of 10 evaluators to calculate the average deodorization rate, and evaluate according to the following criteria. <Drug Efficacy (Aroma Deodorization Effect) Test> ◎: 60% ≤ (Average deodorization rate) 〇: 30% ≤ (Average deodorization rate) < 60% ×: (Average deodorization rate) < 30%

[0039] (3) Foaming Performance Test When spraying various foaming drug efficacy-imparting compositions on a stainless steel plate, the foaming and splashing manner (usability) was evaluated according to the following criteria. <Foaming and Splashing Manner (Usability)> ◎: Both foaming and splashing are good 〇: The foam is difficult to splash, or it splashes quickly and is difficult to foam ×: The foam does not splash at all

[0040]

Table 4

[0041] As a result of the test, when it was injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm 2 for 1 second, the foam volume ratio (Y / X), which is the ratio of the maximum value X of the foam volume immediately after injection to the foam volume Y 1 minute after injection, was Y / X ≤ 0.99 for Examples 1 to 13. These examples were excellent in terms of the diffusibility, aroma deodorizing effect, and usability of the aroma deodorizing component. Among them, Examples 2 to 8 and 11 to 13 with Y / X ≤ 0.70 were found to be even more excellent in terms of the diffusibility, aroma deodorizing effect, and usability of the aroma deodorizing component. On the other hand, in Comparative Example 1 that did not satisfy Y / X ≤ 0.99, favorable results were not obtained in any of the diffusibility, aroma deodorizing effect, and usability of the aroma deodorizing component.

[0042] [Effect Test 2: Antifouling Effect Test] (1) Test Example 1 In Example 5, 0.05% by mass of a quaternary ammonium salt polymer compound, which is an antifouling component, was blended instead of 0.05% by mass of Fragrance A, and an aerosol product of Example 14 was obtained in the same manner as in Example 5. The pH of the foaming medicament-imparting composition of this aerosol product was 6.0, and the foam volume ratio (Y / X) was 0.27. The aerosol product of Example 14 was injected into a toilet bowl for 1 second, left for 1 minute, and then water was run. When 3 drops of salad oil were dropped onto this treated toilet bowl and water was run, the salad oil flowed away without sticking to the toilet bowl.

[0043] (2) Test Example 2 In Example 12, 0.05% by mass of a quaternary ammonium salt polymer compound, which is an antifouling component, was blended instead of 0.05% by mass of d-limonene, and an aerosol product of Example 15 was obtained in the same manner as in Example 11. The pH of the foaming medicament-imparting composition of this aerosol product was 6.4, and the foam volume ratio (Y / X) was 0.08. The aerosol product of Example 15 was injected into a toilet bowl for 1 second, left for 1 minute, and then water was run. When 3 drops of salad oil were dropped onto this treated toilet bowl and water was run, the salad oil flowed away without sticking to the toilet bowl.

[0044] [Effect Test 3: Mildew Prevention Effect Test] (1) Test Example 1 In Example 5, instead of 0.05% by mass of Fragrance A, 0.05% by mass of thymol as a mildew-proof component was blended, and an aerosol product of Example 16 was obtained in the same manner as in Example 5. The pH of the foaming medicament-imparting composition of this aerosol product was 6.0, and the foam volume ratio (Y / X) was 0.23. The aerosol product of Example 16 was sprayed onto the bathroom tiles for 1 second, left for 1 minute, then washed away with water, and left for 1 week. As a result, black mold and pink slime did not grow on the treated surface.

[0045] In Example 11, instead of 0.05% by mass of Fragrance A, 0.05% by mass of thymol as a mildew-proof component was blended, and an aerosol product of Example 17 was obtained in the same manner as in Example 11. The pH of the foaming medicament-imparting composition of this aerosol product was 6.4, and the foam volume ratio (Y / X) was 0.09. The aerosol product of Example 17 was sprayed onto the bathroom tiles for 1 second, left for 1 minute, then washed away with water, and left for 1 week. As a result, black mold and pink slime did not grow on the treated surface.

Industrial Applicability

[0046] The foaming medicament-imparting composition of the present invention can improve the diffusibility and medicinal effects of active ingredients such as fragrance deodorizing components, antifouling components, mildew-proof components, antibacterial components, and virus inactivating components in toilet bowls, bathtubs, drain pipes, washing tubs, window glasses, air conditioner filters, filters, aluminum fins of air conditioners, ventilation fans, screen doors, automobiles, etc. Therefore, it may be used in injection products having these medicinal effects.

Claims

1. A composition for imparting a foaming medicinal effect for filling an injection product, The composition contains (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water, The (B) surfactant is one or more selected from the group consisting of polyoxyethylene 2-ethylhexyl ether, alkyl polyglycoside, and coconut oil alkyldimethylamine oxide, The (C) organic solvent is one or more selected from the group consisting of normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, petrolatum, α-olefin oligomer, squalane, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol, 2-phenoxyethanol, ethylene glycol, propylene glycol, 1-phenoxy-2-propanol, 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether, When the composition is injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm ２ The foam volume ratio, which is the ratio of the maximum value X of the foam volume immediately after injection to the foam volume Y after 1 minute of injection, is Y / X ≤ 0.99 for the composition for imparting a foaming medicinal effect.

2. The (B) surfactant is polyoxyethylene 2-ethylhexyl ether, The (C) organic solvent is ethanol, 2-phenoxyethanol, and isoparaffin, The composition for imparting a foaming medicinal effect according to Claim 1, wherein the blending mass ratio of the (A) active ingredient to the (C) organic solvent is 50 ≤ (C) / (A) ≤ 700.

3. The composition for imparting a foaming medicinal effect according to Claim 1 or 2, wherein the (C) organic solvent is blended in an amount of 0.5 to 30% by mass.

4. The foaming composition for imparting medicinal efficacy according to any one of claims 1 to 3, wherein Y / X ≦ 0.

70.

5. The foaming composition for imparting medicinal efficacy according to any one of claims 1 to 4, wherein the pH of the composition is 5.0 to 12.

0.

6. The foaming composition for imparting medicinal efficacy according to any one of claims 1 to 5, wherein the (A) active ingredient is an antifouling component and the medicinal efficacy is an antifouling effect.

7. The foaming composition for imparting medicinal efficacy according to any one of claims 1 to 6, wherein the (A) active ingredient is an aromatic deodorizing component and the medicinal efficacy is an aromatic deodorizing effect.

8. The foaming composition for imparting medicinal efficacy according to claim 7, which is used for a toilet bowl.

9. The foaming composition for imparting medicinal efficacy according to claim 7 or 8, wherein the blending amount of the (A) active ingredient is 0.05 to 2% by mass.

10. An aerosol product obtained by filling an aerosol container with the composition according to any one of claims 1 to 9 and a propellant.

11. A spray product obtained by filling a spray container with the composition according to any one of claims 1 to 9.

12. A method for imparting medicinal efficacy by spraying a foaming composition for imparting medicinal efficacy containing (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water, wherein the (B) surfactant is one or more selected from the group consisting of polyoxyethylene 2-ethylhexyl ether, alkyl polyglycoside, and coconut oil alkyldimethylamine oxide, The above-mentioned (C) organic solvent is one or more selected from the group consisting of normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbon, petrolatum, α-olefin oligomer, squalane, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, 2-phenylethanol, 2-phenoxyethanol, ethylene glycol, propylene glycol, 1-phenoxy-2-propanol, 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether. When the composition is injected into a 300 mL graduated cylinder with a bottom area of 11.3 cm ２ The foam volume ratio, which is the ratio of the maximum value X of the foam volume immediately after injection to the foam volume Y one minute after injection when the composition is injected into the graduated cylinder for 1 second, is Y / X ≤ 0.99 (except when the human body is the object of drug efficacy imparting).

Images